Merck Just Struck Out in Alzheimer's. Again.

With MK-1167 now shelved, Merck is down to one remaining Alzheimer's candidate: MK-2214, a monoclonal antibody that targets a specific form of phosphorylated tau protein. It's in Phase 2 for early Alzheimer's disease. One shot left.

The Numbers That Should Scare Every Drug Developer

Alzheimer's drug development isn't just hard. It's historically, statistically, almost comically difficult.

The overall failure rate for Alzheimer's drugs? 99.6%, according to a major pipeline analysis of compounds tested since 2002. Only about 2% of drugs that reach Phase 2 or Phase 3 actually make it through. And when you break it down by stage, the picture gets even grimmer: 72% fail in Phase 1, 92% in Phase 2, and 98% in Phase 3.

Imagine a restaurant where 99 out of 100 dishes come back to the kitchen. You'd close the place. But in Alzheimer's research, people keep cooking because the stakes are too high to stop.

Wall Street Shrugged

Analysts barely blinked at the news, and that tells you something.

When Merck's verubecestat program collapsed years ago, Leerink analyst Seamus Fernandez cut his Merck price target by just $1 per share (from $67 to $66). Sanford Bernstein's Tim Anderson said his team had "not given BACE compounds the benefit of the doubt" in their models at all. The message was clear: smart money had already written off Merck's Alzheimer's ambitions.

MK-1167 carried even less weight in financial models than verubecestat did. The consensus view is that Merck's growth story lives and dies with oncology, particularly Keytruda. Alzheimer's assets were always treated as lottery tickets, not pillars.

The stock barely moved. Nobody was surprised.

The Field Isn't Dying; It's Consolidating

While Merck keeps stumbling, the Alzheimer's market is actually booming, just not for everyone.

Two anti-amyloid antibodies now dominate the space: lecanemab (Leqembi) from Eisai and Biogen, and donanemab (Kisunla) from Eli Lilly. Both received full FDA approval and are generating real revenue.

Donanemab has a clever twist that appeals to doctors and insurers alike. It targets mature amyloid plaques, clears them, and then patients can stop treatment. That "clear and stop" model is a fundamentally different value proposition from lecanemab's continuous dosing regimen. Multiple analysts expect donanemab to overtake lecanemab in sales within about a year of full global launch.

The broader pipeline isn't shrinking, either. In 2025, there were 182 clinical trials testing 138 drugs. By 2026, that number grew to 192 trials and 158 unique agents. Major pharma companies are pouring money into Alzheimer's through acquisitions: AbbVie bought Aliada Therapeutics for $1.4 billion in late 2024, Johnson & Johnson acquired Intra-Cellular Therapies for roughly $14.6 billion, and Sanofi picked up Vigil Neuroscience for $470 million to get an oral TREM2 agonist for neuroinflammation.

This isn't a field in retreat. It's a field where the winners are separating from the losers.

What Comes Next for Merck's Brain

Merck now faces an uncomfortable strategic question. MK-2214, their tau-targeting antibody, is the last Alzheimer's asset standing in their pipeline. If it works, Merck stays relevant in neuroscience. If it doesn't, the company's CNS credibility takes another hit, and investors will wonder why Merck keeps trying.

The broader lesson here is sobering but important. Alzheimer's doesn't reward clever mechanisms or elegant science alone. It rewards brute-force persistence, massive patient populations, and a willingness to absorb failure after failure. Eisai spent decades on amyloid before lecanemab paid off. Lilly weathered its own string of setbacks before donanemab clicked.

Merck isn't giving up on the brain. But the brain, so far, hasn't given Merck much to work with.

AstraZeneca Just Bet $1.77B That Your Kidneys Are the Next Big Thing

AstraZeneca agreed to pay up to $1.77 billion for two kidney disease molecules that don't even exist yet, and it's actually the third massive deal they've signed with the same Chinese partner. When big pharma starts throwing billion-dollar checks at your organs, it's time to pay attention.